Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cytokine. 2000 Jul; 12(7):835-44.
Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets.
Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM
Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis. 2018 09; 41(5):819-827.
Hepatocellular carcinoma in Gaucher disease: an international case series.
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002 Nov 15; 100(10):3457-69.
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.
Abel GA, Hays JT, Decker PA, Croghan GA, Kuter DJ, Rigotti NA
Effects of biochemically confirmed smoking cessation on white blood cell count. Mayo Clin Proc. 2005 Aug; 80(8):1022-8.
Effects of biochemically confirmed smoking cessation on white blood cell count.
Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH
ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion. 2009 Feb; 49(2):206-13.
ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13.
The use of PEG-rhuMGDF in platelet apheresis. Stem Cells. 1998; 16 Suppl 2:231-42.
The use of PEG-rhuMGDF in platelet apheresis.
Regulation of megakaryocyte ploidy in vivo in the rat. Blood. 1990 Jan 01; 75(1):74-81.
Regulation of megakaryocyte ploidy in vivo in the rat.
Whatever happened to thrombopoietin? Transfusion. 2002 Mar; 42(3):279-83.
Lennerz JK, Kuter DJ, Hasserjian R, Iafrate J
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm. Hepatology. 2010 Nov; 52(5):1855-6.
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm.
Romiplostim. Cancer Treat Res. 2011; 157:267-88.
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19; 355(16):1672-81.
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
Bell DF, Harris WH, Kuter DJ, Wessinger SJ
Elevated partial thromboplastin time as an indicator of hemorrhagic risk in postoperative patients on warfarin prophylaxis. J Arthroplasty. 1988; 3(2):181-4.
Elevated partial thromboplastin time as an indicator of hemorrhagic risk in postoperative patients on warfarin prophylaxis.
Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ
Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018 07; 182(1):106-113.
Romiplostim for the management of perioperative thrombocytopenia.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14; 115(2):168-86.
International consensus report on the investigation and management of primary immune thrombocytopenia.
Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018 09; 103(9):1433-1443.
Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.
Apoptosis in platelets during ex vivo storage. Vox Sang. 2002 Aug; 83 Suppl 1:311-3.
Apoptosis in platelets during ex vivo storage.
Neutrophil-erythrocyte rosettes in autoimmune hemolytic anemia. Am J Hematol. 2013 Apr; 88(4):333-4.
Neutrophil-erythrocyte rosettes in autoimmune hemolytic anemia.
Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013 May; 161(3):411-23.
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol. 2018 10; 183(2):168.
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
British journal of clinical pharmacology
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018 11; 84(11):2673-2677.
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
Linear free energy relationships predict coordination and p-stacking interactions of small molecules with ferriprotoporphyrin IX. J Inorg Biochem. 2011 May; 105(5):684-92.
Linear free energy relationships predict coordination and p-stacking interactions of small molecules with ferriprotoporphyrin IX.
Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009 Oct 29; 114(18):3748-56.
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Soupir CP, Vergilio JA, Kelly E, Dal Cin P, Kuter D, Hasserjian RP
Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol. 2009 Mar; 144(5):800-2.
Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura.
New thrombopoietic growth factors. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S347-56.
Ismailova A, Kuter D, Bohle DS, Butler IS
An Overview of the Potential Therapeutic Applications of CO-Releasing Molecules. Bioinorg Chem Appl. 2018; 2018:8547364.
An Overview of the Potential Therapeutic Applications of CO-Releasing Molecules.
Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ
Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019 02; 285(2):223-231.
Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018 12; 93(12):1501-1508.
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995 May 15; 85(10):2720-30.
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.
Rabin DU, Kuter DJ, Liebman HA, Bussel JB
What do healthcare providers ask their patients with immune thrombocytopenia? Am J Hematol. 2010 Aug; 85(8):629-31.
What do healthcare providers ask their patients with immune thrombocytopenia?
McCullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D, Eapen M, Hirsch B, Kuter D, Lazarus E, Pamphilon D, Stroncek D, Sugarman J, Wilson R
Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. Transfusion. 2008 Sep; 48(9):2008-25.
Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.
Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB
Journal of thrombosis and haemostasis : JTH
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010 Dec; 8(12):2642-50.
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.
Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol. 2018 11; 183(3):466-478.
Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. Haematologica. 2018 10; 103(10):e492-e495.
Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations.
The protein composition of HeLa ribosomal subunits and nucleolar precursor particles. Exp Cell Res. 1976 Oct 01; 102(1):205-12.
The protein composition of HeLa ribosomal subunits and nucleolar precursor particles.
Progress in clinical and biological research
Platelets contain several inhibitors of megakaryocyte growth and ploidization. Prog Clin Biol Res. 1990; 356:245-57.
Platelets contain several inhibitors of megakaryocyte growth and ploidization.
rmIL-6 stimulates the transcriptional activity of the rat PF4 gene. Exp Hematol. 1995 May; 23(5):397-401.
rmIL-6 stimulates the transcriptional activity of the rat PF4 gene.
Bianchi P, Fermo E, Glader B, Kanno H, Agarwal A, Barcellini W, Eber S, Hoyer JD, Kuter DJ, Maia TM, Mañu-Pereira MDM, Kalfa TA, Pissard S, Segovia JC, van Beers E, Gallagher PG, Rees DC, van Wijk R
Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. Am J Hematol. 2019 01; 94(1):149-161.
Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency.
Biology and chemistry of thrombopoietic agents. Semin Hematol. 2010 Jul; 47(3):243-8.
Biology and chemistry of thrombopoietic agents.
Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, Zimran A
Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J. 2019 05; 49(5):578-591.
Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.
Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Ann Hematol. 2019 Mar; 98(3):581-588.
Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood. 1994 Sep 01; 84(5):1464-72.
Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit.
Rosen EA, Vallurupalli M, Choy E, Lennerz JK, Kuter DJ
Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report. Medicine (Baltimore). 2018 Nov; 97(47):e13321.
Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report.
Dubar F, Egan TJ, Pradines B, Kuter D, Ncokazi KK, Forge D, Paul JF, Pierrot C, Kalamou H, Khalife J, Buisine E, Rogier C, Vezin H, Forfar I, Slomianny C, Trivelli X, Kapishnikov S, Leiserowitz L, Dive D, Biot C
The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem Biol. 2011 Mar 18; 6(3):275-87.
The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance.
Colwell AS, Reish RG, Kuter DJ, Damjanovic B, Austen WG, Fogerty AE
Abdominal contouring procedures increase activity of the coagulation cascade. Ann Plast Surg. 2012 Aug; 69(2):129-33.
Abdominal contouring procedures increase activity of the coagulation cascade.
Reddy P, Atay JK, Selbovitz LG, Connors JM, Piazza G, Block CC, Arpino PA, Berliner N, Hutter AM, Fischer MA, Kuter D, Weitzman J, Sherwood GK, Almozlino A, Giugliano RP
Dabigatran: a review of clinical and pharmacoeconomic evidence. Crit Pathw Cardiol. 2011 Sep; 10(3):117-27.
Dabigatran: a review of clinical and pharmacoeconomic evidence.
Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR
Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012 May; 87(5):558-61.
Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
Nagrebetsky A, Al-Samkari H, Davis NM, Kuter DJ, Wiener-Kronish JP
Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth. 2019 Jan; 122(1):19-31.
Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies.
In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. J Biol Chem. 1987 Mar 05; 262(7):3269-77.
In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor.
Ravid K, Kuter DJ, Beeler DL, Doi T, Rosenberg RD
Selection of an HEL-derived cell line expressing high levels of platelet factor 4. Blood. 1993 Jun 01; 81(11):2885-90.
Selection of an HEL-derived cell line expressing high levels of platelet factor 4.
The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999 May; 105(2):478-85.
The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat.
Cancer, coagulation, and anticoagulation. Oncologist. 1999; 4(6):443-9.
Cancer, coagulation, and anticoagulation.
The physiology of platelet production. Stem Cells. 1996; 14 Suppl 1:88-101.
Moore A, Lau E, Yang C, Mackool B, Kuter DJ
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. Am J Clin Oncol. 2007 Jun; 30(3):329-31.
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
Hematology/oncology clinics of North America
Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1193-211.
Thrombopoietin and platelet production in chronic immune thrombocytopenia.
Al-Samkari H, Patel AA, Schiano TD, Kuter DJ
Recurrence of Acute Intermittent Porphyria After Liver Transplantation. Ann Intern Med. 2019 06 18; 170(12):904-905.
Recurrence of Acute Intermittent Porphyria After Liver Transplantation.
Guddati AK, Rosovsky RP, Van Cott EM, Kuter DJ
International journal of laboratory hematology
Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. Int J Lab Hematol. 2019 Jun; 41(3):325-330.
Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019 05; 185(3):503-513.
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.
Kuter D, Suárez L, Dodd EL, Noll BC, Stephens PW, Bohle DS
Chemistry (Weinheim an der Bergstrasse, Germany)
Hydrating the Bispropionate Notch in Malaria Pigment: A New Structural Motif in the Iron(III)(deuteroporphyrin) Dimer. Chemistry. 2019 Mar 21; 25(17):4373-4378.
Hydrating the Bispropionate Notch in Malaria Pigment: A New Structural Motif in the Iron(III)(deuteroporphyrin) Dimer.
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019; 10:2040620719841735.
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
Professor of Pediatrics and Medicine, Emeritus
Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, Parasuraman S, Colucci P, Paranagama D, Savona MR, Mesa R
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):579-584.e1.
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
DeFilipp Z, Makar RS, Brown J, Avigan D, Chen YB, Cutler CS, Ballen KK, Kuter DJ
Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplant. 2020 06; 55(6):1178-1180.
Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation.
Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. Br J Haematol. 2019 11; 187(3):e61-e64.
Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count.
Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. Blood Adv. 2019 11 26; 3(22):3515-3521.
Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ
Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 11 26; 3(22):3780-3817.
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
VanderSchee CR, Kuter D, Chou H, Jackson BP, Mann KK, Bohle DS
Addressing K/L-edge overlap in elemental analysis from micro-X-ray fluorescence: bioimaging of tungsten and zinc in bone tissue using synchrotron radiation and laser ablation inductively coupled plasma mass spectrometry. Anal Bioanal Chem. 2020 Jan; 412(2):259-265.
Addressing K/L-edge overlap in elemental analysis from micro-X-ray fluorescence: bioimaging of tungsten and zinc in bone tissue using synchrotron radiation and laser ablation inductively coupled plasma mass spectrometry.
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kühne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK
American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 12 10; 3(23):3829-3866.
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Semin Thromb Hemost. 2020 Apr; 46(3):275-288.
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment.
Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020 05; 41:100648.
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting.
Newland AC, Sánchez-González B, Rejto L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020 02; 95(2):178-187.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Al-Samkari H, Rosovsky RP, Karp Leaf RS, Smith DB, Goodarzi K, Fogerty AE, Sykes DB, Kuter DJ
A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020 01 14; 4(1):9-18.
A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia.
Bloom PP, Rodriguez-Lopez J, Witkin AS, Al-Samkari H, Kuter DJ, Mojtahed A, Luther J
Clinical and translational gastroenterology
Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. Clin Transl Gastroenterol. 2020 01; 11(1):e00118.
Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia.
Grunwald MR, Kuter DJ, Altomare I, Burke JM, Gerds AT, Walshauser MA, Savona MR, Stein B, Oh ST, Colucci P, Parasuraman S, Paranagama D, Mesa R
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):219-225.
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020 06; 95(6):643-651.
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Kuter DJ, Wajnrajch M, Hernandez B, Wang R, Chertkoff R, Zimran A
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. Blood Cells Mol Dis. 2020 05; 82:102418.
Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Mytych DT, Park JK, Kim J, Barger TE, Boshier A, Jawa V, Kuter DJ
Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. Br J Haematol. 2020 09; 190(6):923-932.
Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.
Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, Goodarzi K, Bendapudi PK, Bornikova L, Gupta S, Leaf DE, Kuter DJ, Rosovsky RP
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020 07 23; 136(4):489-500.
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.
Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021 04 01; 106(4):1148-1157.
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
Soffer MD, Bendapudi PK, Roberts DJ, Edelson PK, Kuter DJ, Ecker JL, Bryant A, Goldfarb IT
Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. BMC Pregnancy Childbirth. 2020 Jun 15; 20(1):365.
Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report.
The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020; 11:2040620720912992.
The role of romiplostim for pediatric patients with immune thrombocytopenia.
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. Am J Hematol. 2020 Oct; 95(10):1180-1186.
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia.
Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, Vázquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica. 2021 08 01; 106(8):2161-2169.
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
Research and practice in thrombosis and haemostasis
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features. Res Pract Thromb Haemost. 2020 Jul; 4(5):807-812.
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features.
Al-Samkari H, Song F, Van Cott EM, Kuter DJ, Rosovsky R
Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). Am J Hematol. 2020 12; 95(12):1479-1485.
Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19).
Preparing patients with immune thrombocytopenia for surgery: what are the options? Lancet Haematol. 2020 09; 7(9):e626-e627.
Preparing patients with immune thrombocytopenia for surgery: what are the options?
How J, Leiva O, Bogue T, Fell GG, Bustoros MW, Connell NT, Connors JM, Ghobrial IM, Kuter DJ, Mullally A, Neuberg D, Zwicker JI, Fogerty AE, Hobbs GS
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.
An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother. 2021 Feb; 22(3):273-280.
An evaluation of avatrombopag for the treatment of thrombocytopenia.
Mehta A, Rivero-Arias O, Abdelwahab M, Campbell S, McMillan A, Rolfe MJ, Bright JR, Kuter DJ
Scoring system to facilitate diagnosis of Gaucher disease. Intern Med J. 2020 Dec; 50(12):1538-1546.
Scoring system to facilitate diagnosis of Gaucher disease.
Lozano ML, Godeau B, Grainger J, Matzdorff A, Rodeghiero F, Hippenmeyer J, Kuter DJ
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Rev Hematol. 2020 12; 13(12):1319-1332.
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
Marinacci LX, Simeone FJ, Lundquist AL, Kuter DJ, Mahowald GK
Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. N Engl J Med. 2020 Dec 10; 383(24):2372-2383.
Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia.
Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S
Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 04 08; 384(14):1323-1334.
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood. 2021 05 20; 137(20):2736-2744.
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment.
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Rev. 2021 09; 49:100811.
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. Am J Hematol. 2021 07 01; 96(7):E235-E237.
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
Grant MP, VanderSchee CR, Chou H, Bolt A, Epure LM, Kuter D, Antoniou J, Bohle S, Mann KK, Mwale F
Tungsten accumulates in the intervertebral disc and vertebrae stimulating disc degeneration and upregulating markers of inflammation and pain. Eur Cell Mater. 2021 05 17; 41:517-530.
Tungsten accumulates in the intervertebral disc and vertebrae stimulating disc degeneration and upregulating markers of inflammation and pain.
Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol. 2021 11; 195(3):365-370.
Exacerbation of immune thrombocytopenia following COVID-19 vaccination.
McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, Kilpatrick K, Ghanima W, Christiansen CF, Bahmanyar S, Linder M, Eisen M, Wasser J, Altomare I, Kuter D, Sørensen HT, Kelsh M, Brookhart MA
Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clin Pharmacol Ther. 2021 12; 110(6):1570-1578.
Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia.
Song AB, Goodarzi K, Karp Leaf R, Kuter DJ, Al-Samkari H
Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. Am J Hematol. 2021 12 01; 96(12):1563-1568.
Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
Lee EJ, Beltrami-Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, Kruse A, Kessler C, Kruse C, Leavitt AD, Lee AI, Liebman HA, Newland AC, Ray AE, Tarantino MD, Thachil J, Kuter DJ, Cines DB, Bussel JB
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022 03 10; 139(10):1564-1574.
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP.
Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 03; 196(6):1311-1328.
Novel therapies for immune thrombocytopenia.
Hodson L, Visagie KJ, Smith MP, Loots L, Kuter D, Snayer TM, Arnott GE
Chemical communications (Cambridge, England)
Facile synthesis of a C4-symmetrical inherently chiral calix[4]arene. Chem Commun (Camb). 2021 Oct 21; 57(84):11045-11048.
Facile synthesis of a C4-symmetrical inherently chiral calix[4]arene.
Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiró P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E
Liver international : official journal of the International Association for the Study of the Liver
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2022 01; 42(1):161-172.
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022 05; 53:100909.
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Kuter DJ, Rogers KA, Boxer MA, Choi M, Agajanian R, Arnold DM, Broome CM, Field JJ, Murakhovskaya I, Numerof R, Tong S
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. Am J Hematol. 2022 06 01; 97(6):691-699.
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Patel P, Jiang X, Reuter C, Su J, Shafer F, Lee M, Berentsen S
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Haematologica. 2022 07 01; 107(7):1698-1702.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Kuter DJ, Efraim M, Mayer J, Trnený M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 04 14; 386(15):1421-1431.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Nakajima A, Mitomo S, Yuki H, Araki M, Seegers LM, McNulty I, Lee H, Kuter D, Ishibashi M, Kobayashi K, Dijkstra J, Onishi H, Yabushita H, Matsuoka S, Kawamoto H, Watanabe Y, Tanaka K, Chou S, Naganuma T, Okutsu M, Tahara S, Kurita N, Nakamura S, Das S, Nakamura S, Jang IK
Journal of the American Heart Association
Gut Microbiota and Coronary Plaque Characteristics. J Am Heart Assoc. 2022 09 06; 11(17):e026036.
Gut Microbiota and Coronary Plaque Characteristics.
Rilzabrutinib in Immune Thrombocytopenia. Reply. N Engl J Med. 2022 06 30; 386(26):2538.
Rilzabrutinib in Immune Thrombocytopenia. Reply.
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica. 2022 06 01; 107(6):1243-1263.
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.
Nakajima A, Libby P, Mitomo S, Yuki H, Araki M, Seegers LM, McNulty I, Lee H, Ishibashi M, Kobayashi K, Dijkstra J, Ouchi T, Onishi H, Yabushita H, Matsuoka S, Kawamoto H, Watanabe Y, Tanaka K, Chou S, Sato T, Naganuma T, Okutsu M, Tahara S, Kurita N, Nakamura S, Kuter DJ, Nakamura S, Jang IK
Biomarkers associated with coronary high-risk plaques. J Thromb Thrombolysis. 2022 Nov; 54(4):647-659.
Biomarkers associated with coronary high-risk plaques.
Röth A, Barcellini W, Tvedt THA, Miyakawa Y, Kuter DJ, Su J, Jiang X, Hobbs W, Arias JM, Shafer F, Weitz IC
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study. Ann Hematol. 2022 Oct; 101(10):2169-2177.
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Ayad N, Grace RF, Kuter DJ, Al-Samkari H
Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia. Blood. 2022 12 29; 140(26):2849-2852.
Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia.
Hematological support of patients with significant anemia who decline red blood cell blood transfusion. Am J Hematol. 2022 11; 97(11):E430-E432.
Hematological support of patients with significant anemia who decline red blood cell blood transfusion.
Broome CM, Röth A, Kuter DJ, Scully M, Smith R, Wang J, Reuter C, Hobbs W, Daak A
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia. Blood Adv. 2023 03 28; 7(6):987-996.
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia.
VanderSchee CR, Frier D, Kuter D, Mann KK, Jackson BP, Bohle DS
Journal of analytical atomic spectrometry
Quantification of local zinc and tungsten deposits in bone with LA-ICP-MS using novel hydroxyapatite-collagen calibration standards. J Anal At Spectrom. 2021 Nov; 36(11):2431-2438.
Quantification of local zinc and tungsten deposits in bone with LA-ICP-MS using novel hydroxyapatite-collagen calibration standards.
Hematology. American Society of Hematology. Education Program
Warm autoimmune hemolytic anemia and the best treatment strategies. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):105-113.
Warm autoimmune hemolytic anemia and the best treatment strategies.
Kulasekararaj AG, Kuter DJ, Griffin M, Weitz IC, Röth A
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Rev. 2023 05; 59:101041.
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.
Kuter DJ, Bonkovsky HL, Monroy S, Ross G, Guillén-Navarro E, Cappellini MD, Minder AE, Hother-Nielsen O, Ventura P, Jia G, Sweetser MT, Thapar M
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. J Hepatol. 2023 Nov; 79(5):1150-1158.
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
Atthota S, MacDonald A, Markmann JF, Kuter D, Elias N, Yeh H, Dzik WH, Dageforde LA
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Donor-derived disorders of hemostasis and thrombosis in liver transplantation: Considerations for deceased donor liver selection. Liver Transpl. 2023 10 01; 29(10):1109-1117.
Donor-derived disorders of hemostasis and thrombosis in liver transplantation: Considerations for deceased donor liver selection.
Kimani SW, Owen J, Green SR, Li F, Li Y, Dong A, Brown PJ, Ackloo S, Kuter D, Yang C, MacAskill M, MacKinnon SS, Arrowsmith CH, Schapira M, Shahani V, Halabelian L
Journal of chemical information and modeling
Discovery of a Novel DCAF1 Ligand Using a Drug-Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets. J Chem Inf Model. 2023 07 10; 63(13):4070-4078.
Discovery of a Novel DCAF1 Ligand Using a Drug-Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets.
Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Yoo R, Jayawardene D, Vagge DS, Kralova K, Shafer F, Ward?cki M, Lee M, Berentsen S
Sustained inhibition of complement C1s with sutimlimab over 2?years in patients with cold agglutinin disease. Am J Hematol. 2023 08; 98(8):1246-1253.
Sustained inhibition of complement C1s with sutimlimab over 2?years in patients with cold agglutinin disease.
ITP definitions: Time for an update. Br J Haematol. 2023 06; 201(5):1005-1006.
Tiemeyer KH, Kuter DJ, Cairo CW, Hollenhorst MA
New insights into the glycobiology of immune thrombocytopenia. Curr Opin Hematol. 2023 11 01; 30(6):210-218.
New insights into the glycobiology of immune thrombocytopenia.
Revel-Vilk S, Mansfield R, Feder-Krengel N, Machtiger-Azoulay N, Kuter D, Szer J, Rosenbaum H, Ferreira DC, Ruhrman-Shahar N, Wajnrajch M, Zimran A
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study. J Clin Med. 2023 Sep 12; 12(18).
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023 11 04; 402(10413):1648-1659.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Kuter DJ, Bussel JB, Ghanima W, Cooper N, Gernsheimer T, Lambert MP, Liebman HA, Tarantino MD, Lee M, Guo H, Daak A
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study. Ther Adv Hematol. 2023; 14:20406207231205431.
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study.
Kuter DJ, Piatek C, Röth A, Siddiqui A, Numerof RP, Dummer W
Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). Am J Hematol. 2024 01; 99(1):79-87.
Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
How I treat thrombocytopenia in pregnancy. Blood. 2024 02 29; 143(9):747-756.
How I treat thrombocytopenia in pregnancy.
Virk ZM, Leaf RK, Kuter DJ, Goodarzi K, Connell NT, Connors JM, Al-Samkari H
Avatrombopag for adults with early versus chronic immune thrombocytopenia. Am J Hematol. 2024 02; 99(2):155-162.
Avatrombopag for adults with early versus chronic immune thrombocytopenia.
Kuter DJ, Mayer J, Efraim M, Bogdanov LH, Baker R, Kaplan Z, Garg M, Trnený M, Choi PY, Jansen AJG, McDonald V, Bird R, Gumulec J, Kostal M, Gernsheimer T, Ghanima W, Daak A, Cooper N
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. Blood Adv. 2024 04 09; 8(7):1715-1724.
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Kuter DJ, Cataland SR, Broome CM, Neunert C
The latest insights into rare blood disorders: Diagnosis and treatment strategies. Am J Hematol. 2025 Jul; 100(7):1118.
The latest insights into rare blood disorders: Diagnosis and treatment strategies.
Röth A, Barcellini W, Anderson Tvedt TH, Miyakawa Y, Kuter DJ, Su J, Jiang X, Hobbs W, Morales J, Shafer F, Weitz IC
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study. Ann Hematol. 2024 May; 103(5):1803.
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.
Cognitive impairment among patients with chronic immune thrombocytopenia. Br J Haematol. 2024 Jul; 205(1):291-299.
Cognitive impairment among patients with chronic immune thrombocytopenia.
Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A
Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013 Aug; 51(2):116-24.
Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.
Fitzsimons MG, Walton K, Makar R, Dzik W, Kuter D, Vlahakes GJ
Redo aortic valve replacement in a patient with immunoglobulin A deficiency and hemophilia A. Ann Thorac Surg. 2013 Jul; 96(1):311-3.
Redo aortic valve replacement in a patient with immunoglobulin A deficiency and hemophilia A.
Nsumiwa S, Kuter D, Wittlin S, Chibale K, Egan TJ
Structure-activity relationships for ferriprotoporphyrin IX association and ß-hematin inhibition by 4-aminoquinolines using experimental and ab initio methods. Bioorg Med Chem. 2013 Jul 01; 21(13):3738-48.
Structure-activity relationships for ferriprotoporphyrin IX association and ß-hematin inhibition by 4-aminoquinolines using experimental and ab initio methods.
The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013 Jul; 98(1):10-23.
The biology of thrombopoietin and thrombopoietin receptor agonists.
Cooper N, Bussel JB, Kazmierczak M, Miyakawa Y, Cluck S, Lledó García R, Haier B, Lavrov A, Singh P, Snipes R, Kuter DJ
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension. Br J Haematol. 2025 Feb; 206(2):675-688.
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, Panse J, Pullarkat V, Röth A, Shammo J, Terriou L, Weitz I, Yermilov I, Gibbs S, Broder M, Beenhouwer D, Kuter D
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 2024 Dec; 29(1):2329030.
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
Ramasamy K, Vij R, Kuter D, Cella D, Durie BGM, Abonour R, Rifkin RM, Ailawadhi S, Lee HC, Cowan AJ, Ho C, Dhanasiri S, Fish S, Yu E, Dhamane AD, Fang J, Marshall TS, Samuel A, Liu L, Katz J, Gu T, Jagannath S
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody. Clin Lymphoma Myeloma Leuk. 2025 May; 25(5):337-348.e2.
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Cooper N, Jansen AJG, Bird R, Mayer J, Sholzberg M, Tarantino MD, Garg M, Ypma PF, McDonald V, Percy C, Koštál M, Goncalves I, Bogdanov LH, Gernsheimer TB, Diab R, Yao M, Daak A, Kuter DJ
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. Am J Hematol. 2025 Mar; 100(3):439-449.
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M
Journal of the National Comprehensive Cancer Network : JNCCN
Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1266-90.
Peterson W, Martin R, Arnold D, Carvalho B, Cuker A, Gadsden J, Provan D, Rydz N, Shore E, Kuter D, Kouides P, Lavin M, James P, Engen D, Sholzberg M
Delphi consensus recommendations for neuraxial anesthesia in adults with platelet disorders and coagulation defects: communication from the ISTH SSC Subcommittee on von Willebrand Factor. J Thromb Haemost. 2025 Jun; 23(6):2039-2049.
Delphi consensus recommendations for neuraxial anesthesia in adults with platelet disorders and coagulation defects: communication from the ISTH SSC Subcommittee on von Willebrand Factor.
Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013 Dec; 88(12):1041-4.
Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Kuter DJ, Ghanima W, Cooper N, Liebman HA, Zhang L, Hu Y, Miyakawa Y, Homenda W, Galindo LEM, Basquiera AL, Tan CW, Saydam G, Hütter-Krönke ML, Chai-Adisaksopha C, Gómez-Almaguer D, Tran H, Shin HJ, Dantas da Cunha Junior A, Lazar Z, Izquierdo CP, Kirgner I, Lucchini E, Kuzmina G, Fillitz M, Audia S, Taparia M, Cordoba M, Diab R, Yao M, Gouia I, Lee M, Daak A
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood. 2025 Jun 12; 145(24):2914-2926.
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Rituximab therapy for factor II inhibitor in a patient with antiphospholipid antibody syndrome. Blood Coagul Fibrinolysis. 2014 Apr; 25(3):289-91.
Rituximab therapy for factor II inhibitor in a patient with antiphospholipid antibody syndrome.
Multiple spectroscopic and magnetic techniques show that chloroquine induces formation of the µ-oxo dimer of ferriprotoporphyrin IX. J Inorg Biochem. 2014 Apr; 133:40-9.
Multiple spectroscopic and magnetic techniques show that chloroquine induces formation of the µ-oxo dimer of ferriprotoporphyrin IX.
Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014 Apr; 165(2):248-58.
Milestones in understanding platelet production: a historical overview.
Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19; 123(25):3887-94.
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjønnfjord E, Munthe LA, Drivet E, Kared H, Sørvoll IH, Ahlen MT, Mahévas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W
Safety and efficacy of daratumumab in immune thrombocytopenia. Blood Adv. 2026 Jan 13; 10(1):143-154.
Safety and efficacy of daratumumab in immune thrombocytopenia.
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. Immunotherapy. 2025 Aug; 17(11):767-782.
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.
Thibaud JL, Salomane N, Harries S, Wicht KJ, Coulson LB, Kuter D, Chibale K, de Villiers KA
Small Molecule Kinase Inhibitors with In Vitro ß-Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine Learning. ChemMedChem. 2026 Feb 12; 21(3):e202500756.
Small Molecule Kinase Inhibitors with In Vitro ß-Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine Learning.
Evans syndrome revisited. Blood Rev. 2025 Nov; 74:101322.
Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study. Br J Haematol. 2025 Nov; 207(5):2192-2195.
Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.
Thibaud JL, Myburgh DC, Sandlin RD, Fong KY, Garnie LF, Wicht KJ, Kuter D, Wright DW, Egan TJ, de Villiers KA
Exploration of Antiplasmodium Chemical Space Identifies New Inhibitors of ß-Hematin Formation from Areas of Enrichment. ChemMedChem. 2026 Feb 12; 21(3):e202500752.
Exploration of Antiplasmodium Chemical Space Identifies New Inhibitors of ß-Hematin Formation from Areas of Enrichment.
Shammo J, Hillmen P, Blandino P, Abilash V, Kuter DJ
International journal of molecular sciences
Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. Int J Mol Sci. 2025 Oct 15; 26(20).
Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria.
Kuter D, Streltsov V, Davydova N, Venter GA, Naidoo KJ, Egan TJ
Molecular structures and solvation of free monomeric and dimeric ferriheme in aqueous solution: insights from molecular dynamics simulations and extended X-ray absorption fine structure spectroscopy. Inorg Chem. 2014 Oct 20; 53(20):10811-24.
Molecular structures and solvation of free monomeric and dimeric ferriheme in aqueous solution: insights from molecular dynamics simulations and extended X-ray absorption fine structure spectroscopy.
TPO concentrations and response to romiplostim. Am J Hematol. 2014 Dec; 89(12):1155-6.
TPO concentrations and response to romiplostim.
Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015 Apr; 29(4):282-94.
Managing thrombocytopenia associated with cancer chemotherapy.
Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015 Mar; 101(3):255-63.
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Gildenhuys J, Sammy CJ, Müller R, Streltsov VA, le Roex T, Kuter D, de Villiers KA
Dalton transactions (Cambridge, England : 2003)
Alkoxide coordination of iron(III) protoporphyrin IX by antimalarial quinoline methanols: a key interaction observed in the solid-state and solution. Dalton Trans. 2015 Oct 14; 44(38):16767-77.
Alkoxide coordination of iron(III) protoporphyrin IX by antimalarial quinoline methanols: a key interaction observed in the solid-state and solution.
Romiplostim in the management of the thrombocytopenic surgical patient. Transfusion. 2015 Oct; 55(10):2505-10.
Romiplostim in the management of the thrombocytopenic surgical patient.
Solution structures of chloroquine-ferriheme complexes modeled using MD simulation and investigated by EXAFS spectroscopy. J Inorg Biochem. 2016 Jan; 154:114-25.
Solution structures of chloroquine-ferriheme complexes modeled using MD simulation and investigated by EXAFS spectroscopy.
Kim PG, Suh J, Adelman MW, Oduro K, Williams E, Brunner AM, Kuter DJ
Pure White Cell Aplasia and Necrotizing Myositis. Case Rep Hematol. 2016; 2016:4161679.
Pure White Cell Aplasia and Necrotizing Myositis.
Lubberts B, Paulino Pereira NR, Kabrhel C, Kuter DJ, DiGiovanni CW
What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis. Thromb Haemost. 2016 08 30; 116(3):417-31.
What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis.
MGH Transfusion Medicine and Hemostasis Network Clinical Core Center
A Proteogenomic Analysis of Platelets in Patients with Essential Thrombocythemia
MOLECULAR AND CELLULAR MECHANISMS OF PLATELET VIABILITY
Best practice & research. Clinical haematology
What is the role of novel thrombopoietic agents in the management of acute leukemia? Best Pract Res Clin Haematol. 2016 12; 29(4):372-378.
What is the role of novel thrombopoietic agents in the management of acute leukemia?
Lyons AE, Balasubramanian L, Andritsos LA, Evens A, Kuzel T, Vose JM, Bierman PJ, Kuter DJ, Devine SM, Bennett CL
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Hematologic malignancies developing in previously healthy individuals who received hematopoietic growth factors: Implications for use of colony stimulating factors in healthy volunteers participating in early phase clinical studies and in healthy blood product donors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2559.
Hematologic malignancies developing in previously healthy individuals who received hematopoietic growth factors: Implications for use of colony stimulating factors in healthy volunteers participating in early phase clinical studies and in healthy blood product donors.
IgG antibodies against bovine serum albumin in humans--their prevalence and response to exposure to bovine serum albumin. J Immunol Methods. 2005 May; 300(1-2):1-11.
IgG antibodies against bovine serum albumin in humans--their prevalence and response to exposure to bovine serum albumin.
Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apher. 1996; 11(3):149-59.
Thrombopoietin: biology, clinical applications, role in the donor setting.
Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med. 1998 Jul; 105(1):27-32.
Association of thrombocytopenia with the use of intra-aortic balloon pumps.
Apoptosis in transfusion medicine: of death and dying--is that all there is? Transfusion. 2000 Feb; 40(2):135-8.
Apoptosis in transfusion medicine: of death and dying--is that all there is?
The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol. 2000 Dec; 111(3):943-53.
The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
Allgood GS, Kuter DJ, Roll KT, Taylor SL, Zorich NL
Regulatory toxicology and pharmacology : RTP
Postmarketing surveillance of new food ingredients: results from the program with the fat replacer olestra. Regul Toxicol Pharmacol. 2001 Apr; 33(2):224-33.
Postmarketing surveillance of new food ingredients: results from the program with the fat replacer olestra.
Marshall AL, Scarpone R, De Greef M, Bird R, Kuter DJ
Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica. 2016 12; 101(12):e476-e478.
Remissions after long-term use of romiplostim for immune thrombocytopenia.
Thrombopoietin: Biology and Clinical Applications. Oncologist. 1996; 1(1 & 2):98-106.
Thrombopoietin: Biology and Clinical Applications.
Future directions with platelet growth factors. Semin Hematol. 2000 Apr; 37(2 Suppl 4):41-9.
Future directions with platelet growth factors.
Valeri CR, Ragno G, Marks PW, Kuter DJ, Rosenberg RD, Stossel TP
Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 days. Transfusion. 2004 Jun; 44(6):865-70.
Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 days.
Thrombopoietins and thrombopoiesis: a clinical perspective. Vox Sang. 1998; 74 Suppl 2:75-85.
Thrombopoietins and thrombopoiesis: a clinical perspective.
Kuter DJ, Konkle BA, Hamza TH, Uhl L, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais BS, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland JG, Neufeld E, Bussel JB, Ortel TL
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. Am J Hematol. 2017 Aug; 92(8):730-738.
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.
Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am. 2005 Feb; 19(1):183-202, vii.
Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ
Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001 Dec 01; 98(12):3241-8.
Thrombocytopenia caused by the development of antibodies to thrombopoietin.
Trombopoietin: from molecule to medicine. Preface. Stem Cells. 1998; 16 Suppl 2:xi-xii.
Trombopoietin: from molecule to medicine. Preface.
Ravid K, Doi T, Beeler DL, Kuter DJ, Rosenberg RD
Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol. 1991 Dec; 11(12):6116-27.
Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site.
The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost. 2001 Jun; 85(6):979-85.
The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
The end is just the beginning: megakaryocyte apoptosis and platelet release. Int J Hematol. 2001 Dec; 74(4):365-74.
The end is just the beginning: megakaryocyte apoptosis and platelet release.
Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ
The mechanism of apoptosis in human platelets during storage. Transfusion. 2000 Nov; 40(11):1320-9.
The mechanism of apoptosis in human platelets during storage.
Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr; 84 Suppl 1:17-23.
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
Experimental and time-dependent density functional theory characterization of the UV-visible spectra of monomeric and µ-oxo dimeric ferriprotoporphyrin IX. Inorg Chem. 2012 Oct 01; 51(19):10233-50.
Experimental and time-dependent density functional theory characterization of the UV-visible spectra of monomeric and µ-oxo dimeric ferriprotoporphyrin IX.
New thrombopoietic growth factors. Blood. 2007 Jun 01; 109(11):4607-16.
Cover art: the watercolor drawings of James Homer Wright. Stem Cells. 1998; 16 Suppl 2:ix-x.
Cover art: the watercolor drawings of James Homer Wright.
Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999 Aug; 106(2):345-56.
Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics.
European journal of haematology. Supplementum
Meeting the treatment challenges of chronic immune thrombocytopenic purpura. Eur J Haematol Suppl. 2008 Feb; (69):1-2.
Meeting the treatment challenges of chronic immune thrombocytopenic purpura.
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ
Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002 Aug; 46(8):2723-6.
Hematologic effects of linezolid: summary of clinical experience.
Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J
Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001 Sep 01; 98(5):1339-45.
Thrombopoietin therapy increases platelet yields in healthy platelet donors.
Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson R, Smith KJ, Raife T, Tomita D, Armstrong S
Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001 Sep 01; 98(5):1346-51.
Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP
Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010 Nov 11; 363(20):1889-99.
Romiplostim or standard of care in patients with immune thrombocytopenia.
Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004; 9(2):207-16.
Thrombotic complications of central venous catheters in cancer patients.
Successful treatment of pure red cell aplasia with autologous stem cell transplantation. Am J Hematol. 2007 Sep; 82(9):812-4.
Successful treatment of pure red cell aplasia with autologous stem cell transplantation.
Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood. 1992 Feb 01; 79(3):619-26.
Transforming growth factor beta inhibits megakaryocyte growth and endomitosis.
Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK
Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Fitzroy SM, Gildenhuys J, Olivier T, Tshililo NO, Kuter D, de Villiers KA
Langmuir : the ACS journal of surfaces and colloids
The Effects of Quinoline and Non-Quinoline Inhibitors on the Kinetics of Lipid-Mediated ß-Hematin Crystallization. Langmuir. 2017 08 01; 33(30):7529-7537.
The Effects of Quinoline and Non-Quinoline Inhibitors on the Kinetics of Lipid-Mediated ß-Hematin Crystallization.
Ribosomal protein differences between animal cells. Exp Cell Res. 1974 Jul; 87(1):186-94.
Ribosomal protein differences between animal cells.
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009; 60:193-206.
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
Head CA, Brugnara C, Martinez-Ruiz R, Kacmarek RM, Bridges KR, Kuter D, Bloch KD, Zapol WM
Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest. 1997 Sep 01; 100(5):1193-8.
Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.
Mechanism of action and clinical trials of Mpl ligand. Curr Opin Hematol. 1997 Sep; 4(5):312-6.
Mechanism of action and clinical trials of Mpl ligand.
Nugmanova A, Pillai G, Nugmanova D, Kuter D
Improving the management of hypertension in Kazakhstan: implications for improving clinical practice, patient behaviours and health outcomes. Glob Public Health. 2008; 3(2):214-31.
Improving the management of hypertension in Kazakhstan: implications for improving clinical practice, patient behaviours and health outcomes.
Corrêa Soares JB, Menezes D, Vannier-Santos MA, Ferreira-Pereira A, Almeida GT, Venancio TM, Verjovski-Almeida S, Zishiri VK, Kuter D, Hunter R, Egan TJ, Oliveira MF
Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols. PLoS Negl Trop Dis. 2009 Jul 14; 3(7):e477.
Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols.
Reversible denaturation of enzymes by sodium dodecyl sulfate. J Biol Chem. 1971 Jul 25; 246(14):4504-9.
Reversible denaturation of enzymes by sodium dodecyl sulfate.
Successful recovery after an overdose of argatroban. Ann Pharmacother. 2006 Feb; 40(2):336-9.
Successful recovery after an overdose of argatroban.
Sirois MG, Simons M, Kuter DJ, Rosenberg RD, Edelman ER
Rat arterial wall retains myointimal hyperplastic potential long after arterial injury. Circulation. 1997 Aug 19; 96(4):1291-8.
Rat arterial wall retains myointimal hyperplastic potential long after arterial injury.
Kuter DJ, Cebon J, Harker LA, Petz LD, McCullough J
Platelet growth factors: potential impact on transfusion medicine. Transfusion. 1999 Mar; 39(3):321-32.
Platelet growth factors: potential impact on transfusion medicine.
Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007 Nov; 139(3):351-62.
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.
Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M
Myeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):914-32.
Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017 11; 122(3):122-129.
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians.
Proceedings of the National Academy of Sciences of the United States of America
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994 Nov 08; 91(23):11104-8.
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.
Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001 Aug; 21(8):1010-3.
Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid.
Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ
Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion. 2003 Jul; 43(7):857-66.
Apoptotic markers are increased in platelets stored at 37 degrees C.
Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis. 2003 Dec 15; 37(12):1609-16.
Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.
Clinical advances in hematology & oncology : H&O
The promise of thrombopoietins in the treatment of ITP. Clin Adv Hematol Oncol. 2005 Jun; 3(6):464-6.
The promise of thrombopoietins in the treatment of ITP.
Analysis of megakaryocyte ploidy in rat bone marrow cultures. Blood. 1989 Nov 01; 74(6):1952-62.
Analysis of megakaryocyte ploidy in rat bone marrow cultures.
Dual-functioning antimalarials that inhibit the chloroquine-resistance transporter. Future Microbiol. 2013 Apr; 8(4):475-89.
Dual-functioning antimalarials that inhibit the chloroquine-resistance transporter.
Thrombopoietin and the TPO receptorduring platelet storage. Transfusion. 2000 Aug; 40(8):976-87.
Thrombopoietin and the TPO receptorduring platelet storage.
What is the potential for thrombopoietic agents in acute leukemia? Best Pract Res Clin Haematol. 2011 Dec; 24(4):553-8.
What is the potential for thrombopoietic agents in acute leukemia?
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Dec; 135(5):642-50.
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 12; 15(12):1520-1541.
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018 04; 103(4):e169-e172.
The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol Suppl. 2008 Feb; (69):9-18.
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 02; 371(9610):395-403.
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009 Mar 05; 113(10):2161-71.
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
Fleischmann KH, Kuter DJ, Coley CM, Rathmell JP
Practice guidelines often fail to keep pace with the rapid evolution of medicine: a call for clinicians to remain vigilant and revisit their own practice patterns. Reg Anesth Pain Med. 2010 Jan-Feb; 35(1):4-7.
Practice guidelines often fail to keep pace with the rapid evolution of medicine: a call for clinicians to remain vigilant and revisit their own practice patterns.
New thrombopoietic agents: introduction. Semin Hematol. 2010 Jul; 47(3):211.
New thrombopoietic agents: introduction.
Serum free light chain analysis. Am J Hematol. 2010 Oct; 85(10):787-90.
Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Pastores GM
Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011 Oct; 34(5):991-1001.
Gastrointestinal disturbances and their management in miglustat-treated patients.
Alonzo MT, Lacuesta TL, Dimaano EM, Kurosu T, Suarez LA, Mapua CA, Akeda Y, Matias RR, Kuter DJ, Nagata S, Natividad FF, Oishi K
Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. J Infect Dis. 2012 Apr 15; 205(8):1321-9.
Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections.
In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands. Curr Opin Hematol. 1997 May; 4(3):163-70.
In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands.
Goodnough LT, Kuter D, McCullough J, Brecher ME
Apheresis platelets: emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. J Clin Apher. 1998; 13(3):114-9.
Apheresis platelets: emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose.
Kakkar AK, Levine MN, Prandoni P, Lee AY, Rasmussen MS, Kuter D
What is the role for antithrombotics in cancer care? Interactive session with panel discussion. Cancer Treat Rev. 2002 Jun; 28(3):157-9.
What is the role for antithrombotics in cancer care? Interactive session with panel discussion.
Botrocetin agglutination of rat megakaryocytes: a rapid method for megakaryocyte isolation. Exp Hematol. 1992 Oct; 20(9):1085-9.
Botrocetin agglutination of rat megakaryocytes: a rapid method for megakaryocyte isolation.